Sarasota County Public Hospital District FY2027 Proposed Budget
The Sarasota County Public Hospital District's tentative operating and capital budget for fiscal year 2027, a pre-adoption draft for the year ending September 30, 2027.
Executive Director, Rehabilitation Services at Sarasota County Public Hospital District
Employing Organization
Team
Decision makers at Sarasota County Public Hospital District
Associate Chief Medical Officer
Chief Financial Officer
Chief Financial Officer
Chief Financial Officer
Chief Information Officer
Key decision makers in the same organization
Public records
Meetings, budgets, and plans from this organization.
The Sarasota County Public Hospital District's tentative operating and capital budget for fiscal year 2027, a pre-adoption draft for the year ending September 30, 2027.
The Sarasota County Public Hospital District's operating and capital budget for fiscal year 2027, ending September 30, 2027, presented as an adopted budget.
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
Verified emails & phones
Accuracy-guaranteed data
Job-change & title updates
Never lose a contact
The board addressed several key agenda items, including recognizing Excel Award winners, receiving medical staff reports regarding delineation of privilege forms for multiple departments, and approving financial reports, including bad debts and charity care. The board approved the purchase of land located at 7602 State Road 64 and authorized the fiscal year 2027 operating and capital budgets, along with the preliminary millage rate. Additionally, the board approved an internal audit plan for fiscal year 2027 and a resolution to apply for an FQHC look-alike status. The President provided updates on organizational performance metrics, the opening of the Milman-Kover Cancer Pavilion, and the 10th anniversary of the level two trauma center.
The Institutional Biosafety Committee conducted a continuing review of the protocol and site for a clinical trial involving intravesical nadofaragene firadenovec. Key discussions included the reaffirmation of BSL-2 containment requirements and the duration of IBC oversight. The committee reviewed facilities and practices for study agent preparation and handling, specifically regarding waste disposal procedures. The protocol was approved, while the site received conditional approval pending the submission of photographic evidence of specified biohazard waste containers in both the preparation and dosing rooms.
Organization signals
Board meetings and buying signals
Salesforce & HubSpot sync
Native two-way integration